Saccharomyces Cerevisiae as a human probiotic
editSaccharomyces Cerevisiae is used as a probiotic in humans and animals. Especially, a strain Saccharomyces cerevisiae var. boulardii is industrially manufatured and clinically used as a medication.
Efficacy and safety of use Saccharomyces Cerevisiae var. boulardii for prevention of several types of diarrhea is considered evidence based[1].
Several clinical and experimental studies have shown that Saccharomyces Cerevisiae var. boulardii is, to lesser or greater extent, useful for prevention or treatment of several gastrointestinal deseases.[2] Moderate quality evidence shown Saccharomyces Cerevisiae var. boulardii to reduce risk of antibiotic-associated diarrhea both in adults[3][2][1] and in children[3][2] and to reduce risk of adverse effects of Helicobacter pylori eradication therapy[4][2][1]. Also some limited evidence support efficacy of Saccharomyces Cerevisiae var. boulardii in prevention (but not treatment) of traveler’s diarrhea[2][1] and, at least as an adjunct medication, in treatment of acute diarrhea in adults and children and of persistent diarrhea in children[2].
In clinical trials S. Cerevisiae var. boulardii was well tolerated by patients, and adverse effects rate was similar to that in control groups (i. e. groups with placebo or no treatment)[3]. No case of S. Cerevisiae var. boulardii fungemia has been reported during clinical trials[1].
In clinical practice, however, cases of fungemia, caused by Saccharomyces Cerevisiae var. boulardii are reported[1][2]. Patients with compromised immunity or those with centeral vascular catheters are at especial risk. Some researchers have recommended not to use Saccharomyces Cerevisiae var. boulardii for treatmet of such patients[1]. Others suggest only that caution must be excercised with it's use in risk group patients[2].
References
edit- ^ a b c d e f g McFarland, Lynne V. (May 14, 2010). "Systematic review and meta-analysis of Saccharomyces boulardii in adult patiens". World Journal of Gastroenterology. 16 (18): 2202–2222. doi:10.3748/wjg.v16.i18.2202. Retrieved April 13, 2019.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b c d e f g h Kelesidis, Theodoros; Pothoulakis, Chralabos (November 11, 2011). "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders". Therapeutic Advances in Gastroenterology. 5 (2): 111–125. doi:10.1177/1756283X11428502. Retrieved April 13, 2019.
- ^ a b c Szajewska, H.; Kolodziej, M. (October 2015). "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7): 793–801. doi:10.1111/apt.13344. Retrieved April 13, 2019.
- ^ Szajewska, H.; Horvath, A.; Kolodziej, M. (June 2015). "Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection". Alimentary Pharmacology & Therapeutics. 41 (12): 1237–1245. doi:10.1111/apt.13214. Retrieved April 13, 2019.
Literature
edit- McFarland, Lynne V. (May 14, 2010). "Systematic review and meta-analysis of Saccharomyces boulardii in adult patiens". World Journal of Gastroenterology. 16 (18): 2202–2222. doi:10.3748/wjg.v16.i18.2202. Retrieved April 13, 2019.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - Kelesidis, Theodoros; Pothoulakis, Chralabos (November 11, 2011). "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders". Therapeutic Advances in Gastroenterology. 5 (2): 111–125. doi:10.1177/1756283X11428502. Retrieved April 13, 2019.
- Szajewska, H.; Kolodziej, M. (October 2015). "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7): 793–801. doi:10.1111/apt.13344. Retrieved April 13, 2019.
- Szajewska, H.; Horvath, A.; Kolodziej, M. (June 2015). "Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection". Alimentary Pharmacology & Therapeutics. 41 (12): 1237–1245. doi:10.1111/apt.13214. Retrieved April 13, 2019.